Table 3.
Migraine-Related Disability and Migraine-Specific Quality of Life.
| Characteristics | Crossover Comparison | |||
|---|---|---|---|---|
| Placebo (n = 62) | Resveratrol (n = 62) | Treatment Difference (Resveratrol–Placebo) | p-Value | |
| Headache impact test-6™ | 59.4 ± 0.9 | 58.7 ± 1.1 | −0.7 ± 0.9 | 0.491 |
| Migraine disability assessment | ||||
| Total score | 15.6 ± 2.3 | 12.6 ± 1.8 | −3.0 ± 2.4 | 0.367 |
| Item A | 9.9 ± 1.0 | 8.7 ± 0.8 | −1.3 ± 0.9 | 0.341 |
| Item B | 5.2 ± 0.2 | 5.4 ± 0.2 | 0.2 ± 0.3 | 0.587 |
| Migraine-specific quality of life | ||||
| Emotional function | 62.9 ± 3.8 | 67.1 ± 3.6 | 4.2 ± 4.2 | 0.253 |
| Role function preventive | 69.9 ± 3.5 | 75.3 ± 3.3 | 5.4 ± 3.3 | 0.106 |
| Role function restrictive | 57.8 ± 3.6 | 62.7 ± 3.6 | 4.9 ± 3.6 | 0.239 |
Wilcoxon Signed-Rank Test used for all comparisons except the Headache Impact Test.